Celltrion, Inc. (KRX:068270) Not Flying Under The Radar
Apr 30
South Korean (KOSPI) Healthcare Sector Analysis
UpdatedMay 01, 2024
DataAggregated Company Financials
Companies351
- 7D1.3%
- 3M6.4%
- 1Y10.5%
- YTD-2.9%
Over the last 7 days, the Healthcare industry has remained flat, although notably Celltrion gained 5.2%. As for the the longer term, the industry is up 9.9% over the past 12 months. Looking forward, earnings are forecast to grow by 32% annually.
Sector Valuation and Performance
Has the South Korean Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 01 May 2024 | ₩236.3t | ₩52.3t | ₩538.5b | 18.4x | 438.7x | 4.5x |
| Fri, 29 Mar 2024 | ₩246.6t | ₩53.1t | ₩656.3b | 18.4x | 375.8x | 4.6x |
| Sun, 25 Feb 2024 | ₩228.6t | ₩52.0t | -₩48,458,490,006.00 | 23x | -4717.4x | 4.4x |
| Tue, 23 Jan 2024 | ₩234.7t | ₩55.7t | ₩55.5b | 22.7x | 4231.9x | 4.2x |
| Thu, 21 Dec 2023 | ₩219.9t | ₩56.1t | ₩280.7b | 21.5x | 783.4x | 3.9x |
| Sat, 18 Nov 2023 | ₩207.8t | ₩56.0t | ₩972.0b | 18.3x | 213.8x | 3.7x |
| Mon, 16 Oct 2023 | ₩204.8t | ₩56.0t | ₩1.0t | 18.7x | 200.1x | 3.7x |
| Wed, 13 Sep 2023 | ₩217.3t | ₩56.0t | ₩932.8b | 20.6x | 233x | 3.9x |
| Fri, 11 Aug 2023 | ₩224.3t | ₩56.1t | ₩2.1t | 23.4x | 107.3x | 4x |
| Sun, 09 Jul 2023 | ₩199.1t | ₩56.1t | ₩2.1t | 20x | 94.6x | 3.5x |
| Tue, 06 Jun 2023 | ₩218.2t | ₩56.3t | ₩2.1t | 20.9x | 103.5x | 3.9x |
| Thu, 04 May 2023 | ₩210.5t | ₩58.4t | ₩3.2t | 21x | 64.8x | 3.6x |
| Sat, 01 Apr 2023 | ₩203.5t | ₩58.3t | ₩3.3t | 19.8x | 62.6x | 3.5x |
| Mon, 27 Feb 2023 | ₩201.1t | ₩57.8t | ₩4.6t | 19.4x | 43.7x | 3.5x |
| Wed, 25 Jan 2023 | ₩203.8t | ₩57.8t | ₩4.6t | 17.4x | 44.2x | 3.5x |
| Fri, 23 Dec 2022 | ₩213.1t | ₩57.5t | ₩3.9t | 16.4x | 54.7x | 3.7x |
| Sun, 20 Nov 2022 | ₩215.1t | ₩56.8t | ₩4.1t | 15.9x | 52.4x | 3.8x |
| Tue, 18 Oct 2022 | ₩192.2t | ₩55.7t | ₩4.1t | 14.9x | 47.2x | 3.4x |
| Thu, 15 Sep 2022 | ₩211.7t | ₩56.0t | ₩4.2t | 17.7x | 50x | 3.8x |
| Sat, 13 Aug 2022 | ₩236.6t | ₩54.2t | ₩3.9t | 21x | 60.9x | 4.4x |
| Mon, 11 Jul 2022 | ₩219.5t | ₩54.2t | ₩3.9t | 18.7x | 56.5x | 4.1x |
| Wed, 08 Jun 2022 | ₩221.5t | ₩54.2t | ₩3.9t | 22.3x | 56.8x | 4.1x |
| Fri, 06 May 2022 | ₩226.2t | ₩51.1t | ₩3.9t | 22.7x | 58.3x | 4.4x |
| Sun, 03 Apr 2022 | ₩232.6t | ₩50.9t | ₩4.0t | 22.4x | 58.2x | 4.6x |
| Tue, 01 Mar 2022 | ₩221.7t | ₩49.0t | ₩4.3t | 21.9x | 51.4x | 4.5x |
| Thu, 27 Jan 2022 | ₩219.0t | ₩49.0t | ₩4.3t | 20.5x | 50.7x | 4.5x |
| Sat, 25 Dec 2021 | ₩259.4t | ₩49.0t | ₩4.3t | 23.7x | 60x | 5.3x |
| Mon, 22 Nov 2021 | ₩262.6t | ₩48.3t | ₩4.4t | 22.1x | 59x | 5.4x |
| Wed, 20 Oct 2021 | ₩269.1t | ₩48.0t | ₩4.3t | 22.6x | 63.1x | 5.6x |
| Fri, 17 Sep 2021 | ₩302.3t | ₩48.2t | ₩4.3t | 26.7x | 70.6x | 6.3x |
| Sun, 15 Aug 2021 | ₩314.6t | ₩49.5t | ₩4.3t | 30.3x | 73.5x | 6.4x |
| Thu, 10 Jun 2021 | ₩276.3t | ₩44.3t | ₩2.9t | 27.4x | 95.6x | 6.2x |
Price to Earnings Ratio
94.5x
Current Industry PE
- Investors are optimistic on the South Korean Healthcare industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 435x which is higher than its 3-year average PE of 171x.
- The industry is trading close to its 3-year average PS ratio of 4.4x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have declined 43% per year over the last three years.
- Meanwhile revenues for these companies have grown 5.7% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the South Korean Healthcare sector?
| KR Market | 2.67% | |
| Healthcare | 1.34% | |
| Healthtech | 5.19% | |
| Biotech | 2.85% | |
| Pharma | 1.50% | |
| Medical Equipment | 1.47% | |
| Healthcare Services | -0.58% | |
| Life Sciences | -0.83% | |
Industry PE
- Investors are most optimistic about the Life Sciences industry even though it's trading below its 3-year average PE ratio of 136x.
- Analysts are expecting annual earnings growth of 17.3%, which is higher than its past year's earnings growth of 8.1% per year.
Forecasted Growth
- Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 113% over the next 5 years.
- In contrast, the Life Sciences industry is expected to see its earnings grow by 17% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A068270 Celltrion | ₩189.00k | 5.3% +₩2.0t | 18.9% | PE73.1x | |
| A028300 HLB | ₩111.20k | 2.5% +₩352.5b | 239.9% | PS338.4x | |
| A326030 SK Biopharmaceuticals | ₩87.60k | 3.1% +₩203.6b | 28.3% | PS19.3x | |
| A068760 Celltrion Pharm | ₩96.10k | 4.6% +₩173.9b | 28.2% | n/a | |
| A214450 PharmaResearch | ₩127.60k | 10.5% +₩123.4b | 23.3% | PE17x |
